NIS (Neuropathy Impairment Score) is a clinically important, sensitive measure of individual neurological function, assessing sensory function, reflexes, and muscle weakness. NIS score ranged from 0 to 244, with higher score indicating greater disability or impairment. The rate of change was calculated from last follow-up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

NIS (Neuropathy Impairment Score) is a clinically important, sensitive measure of individual neurological function, assessing sensory function, reflexes, and muscle weakness. NIS score ranged from 0 to 244, with higher score indicating greater disability or impairment. The rate of change was calculated from last follow-up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

NIS-LL (Neuropathy Impairment Score Lower Limbs) is a clinically important, sensitive measure of neurological function in individuals, assessing sensory function, reflexes, and muscle weakness of the lower limbo. NÍS-LL assessed muscle weakness, reflexes, sensation. Each item is scored separately for left and right limbs. Components of muscle weakness:0(normal) to4(paralysis), higher score=more weakness; reflexes, sensation:0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=more impairment. The rate of change was calculated from last follow-up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Norfolk Quality of Life Questionnaire for Diabetic Neuropathy is a standardized and validated instrument that assesses the effect of polyneuropathy on the functionality and quality of life of the individual. Norfolk QOL-DN: 35-item participant-rated questionnaire is used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -4 to 138, where higher score=worse quality of life.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

COMPASS-31 (Composite Autonomic Symptom Score 31) is a questionnaire designed to assess the severity and functional ability in participants with autonomic dysfunction. COMPASS-31 total score ranged from 0 to 100; where 0=Lesser severity of dysautonomia and 100=Greater severity of dysautonomia.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

FAP-RODS is a questionnaire that assessed the effect of neuropathy on daily activities. FAP-RODS total score ranged from 0 to 68; where, 0=Lower ability to perform daily activities and 68=Greater ability to perform daily activities.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

FAP is a stage system based on symptom severity and disease progression. FAP stages included: Asymptomatic; Free ambulation (walking without support): stage 1; Supportive ambulation (walking with support): stage 2; Wheelchair-bound or bedridden: stage 3.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

PND is a staging system that assess the degree of neuropathic dysfunction and its impact on ambulation. PND stages included: Asymptomatic; Stage I: Sensory disturbances, normal gait; Stage II: Sensory disturbances, altered gait not requiring support; IIIA: Gait requiring one support; IIIB: Gait requiring two supports; IV: Wheelchair or bedside. Participants who did not change to higher stages compared to the start of treatment was reported as Unchanged and those who progressed to higher stages were reported under Staging up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Percentage of responders to treatment at Month 12 was defined as participants who achieved the change from baseline of less than 4 points in the NIS and participants who achieved the change from baseline of less than 2 points in the NIS-LL were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with R-R interval variability (altered/unaltered) was reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for the specified rows.

BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2). mBMI was calculated by multiplying BMI by serum albumin levels [gram/liter (g/L)].

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for the specified rows.

Sural sensory nerve action potential amplitude (in microvolts) was measured using electromyography of the left lower limb.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Peroneal motor nerve compound muscle action potential amplitude was measured using electromyography of the left lower limb.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

NIS (Neuropathy Impairment Score) was a clinically important, sensitive measure of individual neurological function, assessing sensory function, reflexes, and muscle weakness. NIS score ranged from 0 to 244, with higher score indicating greater disability or impairment. The rate of change was calculated from last follow-up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

NIS-LL (Neuropathy Impairment Score Lower Limbs) was clinically important, sensitive measure of neurological function in individuals, assessing sensory function, reflexes, and muscle weakness of the lower limbo. NÍS-LL assessed muscle weakness, reflexes, sensation. Each item scored separately for left and right limbs. Components of muscle weakness:0(normal) to4(paralysis), higher score=more weakness; reflexes, sensation:0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=more impairment. The rate of change was calculated from last follow-up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Norfolk Quality of Life Questionnaire for Diabetic Neuropathy was a standardized and validated instrument that assesses the effect of polyneuropathy on the functionality and quality of life of the individual. Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -4 to 138, where higher score=worse quality of life.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Data was not collected for this outcome measure as data was not available in the medical records.

COMPASS-31 (Composite Autonomic Symptom Score 31) was a questionnaire designed to assess the severity and functional ability in participants with autonomic dysfunction. COMPASS-31 total score ranged from 0 to 100; where 0=Lesser severity of dysautonomia and 100=Greater severity of dysautonomia.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Data was not collected for this outcome measure as data was not available in the medical records.

FAP-RODS is a questionnaire that assessed the effect of neuropathy on daily activities. FAP-RODS total score ranged from 0 to 68; where, 0=Lower ability to perform daily activities and 68=Greater ability to perform daily activities.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Data was not collected for this outcome measure as data was not available in the medical records.

FAP stage is a staging system based on symptom severity and disease progression. FAP stages included: Asymptomatic; Free ambulation (Walking without support): stage 1; Supportive ambulation (Walking with support): stage 2; Wheelchair-bound or bedridden: stage 3.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for the specified rows.

PND was a simple staging system according to the degree of neuropathic dysfunction and its impact on ambulation. PND stages included: Asymptomatic: I Sensory disturbances, normal gait: II Sensory disturbances, altered gait not requiring support: IIIA Gait requiring one support: IIIB Gait requiring two supports: IV Wheelchair or bedside). Participants who did not change to higher stages compared to the start of treatment was reported as Unchanged and those who progressed to higher stages were reported under Staging up.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Percentage of responders to treatment was defined as participants who achieved the change from baseline of less than 4 points in the NIS and participants who achieved the change from baseline of less than 2 points in the NIS-LL were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with R-R interval variability (altered/unaltered) was reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2).

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for the specified rows.

Sural sensory nerve action potential amplitude (in microvolts) was measured using electromyography of the left lower limb.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Peroneal motor nerve compound muscle action potential amplitude (in millivolts) was measured using electromyography of the left lower limb.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Number of participants with carpal tunnel syndrome were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants with lumbar stenosis were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants with gastrointestinal disturbances were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with unintentional weight loss were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, 'Overall Number Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with urological disturbances were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. All participants in the 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with ophthalmological disturbances were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. All participants in the 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with CNS disturbances were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. All participants in the 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with symptoms of autonomic neuropathy including impaired sweating, sexual dysfunction, orthostatic hypotension were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study. All participants in the 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Number of participants with symptoms of peripheral neuropathy (allodynia and paresthesia) were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and analyzed in this study.